Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year High – Should You Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION) reached a new 52-week high during trading on Tuesday . The company traded as high as $51.73 and last traded at $51.5550, with a volume of 318131 shares changing hands. The stock had previously closed at $49.26.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Citizens Jmp restated a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Raymond James Financial reiterated a “strong-buy” rating and set a $59.00 price objective on shares of Sionna Therapeutics in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. JonesTrading boosted their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Finally, Stifel Nicolaus upped their target price on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, May 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $53.89.

Sionna Therapeutics Trading Up 5.1%

The company has a 50-day moving average price of $42.04 and a two-hundred day moving average price of $40.26. The stock has a market cap of $2.25 billion, a P/E ratio of -25.77 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Transactions at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the transaction, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 892,538 shares of company stock valued at $40,656,209. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Viking Global Investors LP grew its position in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Sionna Therapeutics by 30.1% during the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Sionna Therapeutics by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after purchasing an additional 193,613 shares during the period. Finally, State Street Corp grew its holdings in shares of Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.